Non-invasive Diagnosis of Pulmonary Embolism by Use of Biomarkers in Exhaled Breath Condensate (NCT04010760) | Clinical Trial Compass
CompletedNot Applicable
Non-invasive Diagnosis of Pulmonary Embolism by Use of Biomarkers in Exhaled Breath Condensate
Denmark110 participantsStarted 2019-04-08
Plain-language summary
In this study, a new, non-invasive method for diagnosis of pulmonary embolism (PE) will be tested. In pre-clinical studies, we have identified 151 putative biomarkers for pulmonary embolism in the exhaled breath condensate (EBC). These biomarkers needs validation/consolidation in a clinical setting before further test of this new diagnostic method.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria - Suspected/confirmed PE patients:
* Admitted to the emergency department with initial diagnosis of PE, visited to the Department of Cardiology at Aalborg University Hospital.
* Are conscious and able to understand the given study information.
* Possess legal capacity.
* Age above 18 years.
* Informed, signed consent is obtained.
* Clinically stable, which is defined as patients with stable blood pressure and not in need for other treatments .
* No need for organ support, which comprises need for vasopressors or inotropes, mechanical ventilation, extra corporal circulation or renal replacement therapy.
Inclusion Criteria - Controls:
⢠Patients as the PE patients, but where the diagnosis of PE is rejected.
The rest of the control persons will be recruited as described:
* Patients who are going to have elective procedures at the Department of Cardiology, Aalborg University Hospital.
* Same gender and age (within a 10-year range) as an included PE patient.
* Are conscious and able to understand the given study information.
* Possess legal capacity.
* Age above 18 years.
* Informed, signed consent is obtained.
Exclusion Criteria:
* Active malignant disease (i.e. ongoing anti-cancer therapy or palliation).
* Current smokers
What they're measuring
1
Prediction of pulmonary embolism by use of biomarkers in the EBC